Clinical Trials - September 25, 2019
Preliminary results from LIDDS’ Phase IIb trial
The company has announced preliminary data from the LPC-004 study that aimed to determine the tolerability of Liproca Depot and the Prostate-Specific Antigen (PSA) effect at month 5 on patients in part II of the study. The PSA reduction for part II patients was in line with the expected pattern for Liproca® Depot’s sustained release […]
Business article - August 26, 2019
Mini-interview: Monica Wallter, CEO of LIDDS
The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update. What’s next for LIDDS and what results can we […]
In a new job - June 18, 2019
New Project Manager at LIDDS
Erwin Brenndörfer has joined LIDDS as Project Manager Translational Medicine. Erwin will be responsible for managing LIDDS portfolio of pre-clinical studies as well as continuing the development of the NanoZolid technology and identifying new drugs that can be combined with NanoZolid. An Assistant Professor of Infectious Diseases Erwin Brenndörfer has extensive experience in managing pre-clinical […]
Intellectual Property - March 26, 2019
LIDDS’ technology receives US patent
The United States Patent and Trademark Office has issued a Notice of Allowance for the NanoZolid technology patent. The same patent was approved by the European Patent Office in 2018. With this new US patent, the NanoZolid technology will be protected until 2037 in both Europe and in the US. LIDDS will pursue additional patent […]
Clinical Trials - March 6, 2019
Final patient enrolled in LIDDS Phase IIb study
The last patient has been enrolled in the company’s study for the localized treatment of prostate cancer. The Phase IIb study will identify the optimal dose for Phase III and test the safety of Liproca Depot and its effectiveness in stopping cancer progression. Liproca Depot is based on LIDDS NanoZolid drug delivery technology. “We are very […]
Pharma Business - March 5, 2019
Mini-interview: Monica Wallter, CEO of LIDDS
The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update. What’s next for LIDDS and what results can we […]
